The trajectory of Sildenafil presents a challenging picture for investors. While the initial introduction generated significant returns, the end of its patent opened the floodgates to generic competitors, dramatically reducing market share. This creates a specific risk for drug manufacturers depending on similar blockbuster medications, suggesting

The legacy of Viagra, and its creator copyright, presents a intriguing case study for investors. Originally a blockbuster drug, producing billions in revenue , its exclusivity period created a deluge of knock-off medications, significantly diminishing its dominance. While certain firms may seek to capitalize on male sexual dysfunction, the existing